Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice.

2nd Department of Medicine Department of Cardiovascular Medicine 1st Faculty of Medicine Charles University General University Hospital Prague Czech Republic

Amyloidosis Research and Treatment Centre Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Pavia Italy

Belgrade University School of Medicine Cardiology Institute for Rehabilitation Belgrade Serbia

Cardiac Amyloid Clinic Division of Circulatory Failure Department of Cardiovascular Diseases Mayo Clinic Rochester MN USA

Cardiac Amyloidosis Program Centre for Advanced Cardiac Care Columbia University Irving Medical Centre New York Presbyterian Hospital New York NY USA

Cardiologic Centre University of Ferrara Italy

Cardiology Department of Cardiac Thoracic Vascular Sciences and Public Health University of Padova Padova Italy

Cardiomyopathy Service Royal Brompton Hospital London UK

Cardiovascular and Thoracic Department University Cardiology AOU Città della Salute e della Scienza di Torino Torino Italy

Cardiovascular Centre Darmstadt Heidelberg Germany

Cardiovascular Pathology Unit University Hospital Padua Italy

Centre for Molecular and Vascular Biology KU Leuven Leuven Belgium

Department of Cardiac Thoracic and Vascular Sciences and Public Health University of Padua Padua Italy

Department of Cardiology Maastricht University CARIM School for Cardiovascular Diseases Maastricht Netherlands

Department Of Cardiology Philipps University Marburg Marburg Germany

Department of Cardiology University of Heidelberg Germany

Department of Internal Medicine 3 Saarland University Medical Centre Saarland University Homburg Saar Germany

Department of Molecular Medicine University of Pavia Italy

Dipartimento di Scienze Biomediche e Cliniche Università degli Studi d Milano Ospedale Fatebenefratelli Italy

European Reference Network for Rare Low Prevalence and Complex Diseases of the Heart ERN GUARD Heart

French Referral Centre for Cardiac Amyloidosis Amyloidosis Mondor Network GRC Amyloid Research Institute CHU Henri Mondor Créteil France

GZO Zurich Regional Health Centre Wetzikon and Cardioimmunology Centre for Molecular Cardiology University of Zurich Switzerland

Heart Failure and Inherited Cardiac Diseases Unit Department of Cardiology Hospital Universitario Puerta de Hierro Majadahonda CIBERCV Manuel de Falla 2 28222 Madrid Spain

Heart Failure Institute Leviev Heart Centre Sheba Hospital and Sackler School of Medicine Tel Aviv University Israel

ICIN Netherlands Heart Institute Holland Heart House Utrecht Netherlands

Leviev Heart Centre Chaim Sheba Medical Centre Israel

Maria Cecilia Hospital GVM Care and Research Cotignola Italy

Mid German Heart Centre Department of Internal Medicine 3 Division of Cardiology Angiology and Intensive Medical Care University Hospital Halle Martin Luther University Halle Wittenberg Halle Germany

National Amyloidosis Centre Division of Medicine University College London Royal Free Hospital London UK

Universidad Francisco de Vitoria Pozuelo de Alarcon Spain

Zobrazit více v PubMed

Maurer  MS, Elliott  P, Comenzo  R, Semigran  M, Rapezzi  C.  Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation  2017;135:1357–1377. PubMed PMC

Ruberg  FL, Grogan  M, Hanna  M, Kelly  JW, Maurer  MS.  Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol  2019;73:2872–2891. PubMed PMC

Benson  MD, Buxbaum  JN, Eisenberg  DS, Merlini  G, Saraiva  MJM, Sekijima  Y, Sipe  JD, Westermark  P.  Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid  2018;25:215–219. PubMed

Maleszewski  JJ.  Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol  2015;24:343–350. PubMed

Boldrini  M, Cappelli  F, Chacko  L, Restrepo-Cordoba  MA, Lopez-Sainz  A, Giannoni  A, Aimo  A, Baggiano  A, Martinez-Naharro  A, Whelan  C, Quarta  C, Passino  C, Castiglione  V, Chubuchnyi  V, Spini  V, Taddei  C, Vergaro  G, Petrie  A, Ruiz-Guerrero  L, Moñivas  V, Mingo-Santos  S, Mirelis  JG, Dominguez  F, Gonzalez-Lopez  E, Perlini  S, Pontone  G, Gillmore  J, Hawkins  PN, Garcia-Pavia  P, Emdin  M, Fontana  M.  Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging  2020;13:909–920. PubMed

Gillmore  JD, Maurer  MS, Falk  RH, Merlini  G, Damy  T, Dispenzieri  A, Wechalekar  AD, Berk  JL, Quarta  CC, Grogan  M, Lachmann  HJ, Bokhari  S, Castano  A, Dorbala  S, Johnson  GB, Glaudemans  AW, Rezk  T, Fontana  M, Palladini  G, Milani  P, Guidalotti  PL, Flatman  K, Lane  T, Vonberg  FW, Whelan  CJ, Moon  JC, Ruberg  FL, Miller  EJ, Hutt  DF, Hazenberg  BP, Rapezzi  C, Hawkins  PN.  Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation  2016;133:2404–2412. PubMed

Palladini  G, Russo  P, Bosoni  T, Verga  L, Sarais  G, Lavatelli  F, Nuvolone  M, Obici  L, Casarini  S, Donadei  S, Albertini  R, Righetti  G, Marini  M, Graziani  MS, Melzi D'Eril  GV, Moratti  R, Merlini  G.  Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem  2009;55:499–504. PubMed

Sprangers  B, Claes  K, Evenepoel  P, Kuypers  D, Poesen  K, Delforge  M, Bossuyt  VX, Meijers  B.  Comparison of 2 serum-free light-chain assays in CKD patients. Kidney Int Rep  2020;5:627–631. PubMed PMC

Layoun  ME, Desmarais  J, Heitner  SB, Masri  A.  Hot hearts on bone scintigraphy are not all amyloidosis: hydroxychloroquine-induced restrictive cardiomyopathy. Eur Heart J  2020;41:2414–2414. PubMed PMC

López-Sainz  Á, Hernandez-Hernandez  A, Gonzalez-Lopez  E, Domínguez  F, Restrepo-Cordoba  MA, Cobo-Marcos  M, Gómez-Bueno  M, Hernandez-Perez  FJ, Oteo  JF, Mirelis  JG, Cavero  MA, Moñivas  V, Mingo  SS, de Haro-Del Moral  FJ, Krsnik  I, Salas  C, Bornstein  B, Briceño  A, López  JA, Vázquez  J, Alonso-Pulpón  L, Segovia  J., Garcia-Pavia  P.  Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. Rev Esp Cardiol (Engl Ed)  2021;74:149–158. PubMed

González-López  E, Gallego-Delgado  M, Guzzo-Merello  G, de Haro-Del Moral  FJ, Cobo-Marcos  M, Robles  C, Bornstein  B, Salas  C, Lara-Pezzi  E, Alonso-Pulpon  L, Garcia-Pavia  P.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J  2015;36:2585–2594. PubMed

Damy  T, Costes  B, Hagège  AA, Donal  E, Eicher  JC, Slama  M, Guellich  A, Rappeneau  S, Gueffet  JP, Logeart  D, Planté-Bordeneuve  V, Bouvaist  H, Huttin  O, Mulak  G, Dubois-Randé  JL, Goossens  M, Canoui-Poitrine  F, Buxbaum  JN.  Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J  2016;37:1826–1834. PubMed

Castaño  A, Narotsky  DL, Hamid  N, Khalique  OK, Morgenstern  R, DeLuca  A, Rubin  J, Chiuzan  C, Nazif  T, Vahl  T, George  I, Kodali  S, Leon  MB, Hahn  R, Bokhari  S, Maurer  MS.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J  2017;38:2879–2887. PubMed PMC

Sayago  I, Krsnik  I, Gómez-Bueno  M, García-Pavía  P, Jaramillo  N, Salas  C, Mingo  S, Oteo  JF, Alonso-Pulpón  L, Segovia  J.  Analysis of diagnostic and therapeutic strategies in advanced cardiac light-chain amyloidosis. J Heart Lung Transplant  2016;35:995–1002. PubMed

Kumar  S, Dispenzieri  A, Lacy  MQ, Hayman  SR, Buadi  FK, Colby  C, Laumann  K, Zeldenrust  SR, Leung  N, Dingli  D, Greipp  PR, Lust  JA, Russell  SJ, Kyle  RA, Rajkumar  SV, Gertz  MA.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol  2012;30:989–995. PubMed PMC

Lilleness  B, Ruberg  FL, Mussinelli  R, Doros  G, Sanchorawala  V.  Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood  2019;133:215–223. PubMed

Grogan  M, Scott  CG, Kyle  RA, Zeldenrust  SR, Gertz  MA, Lin  G, Klarich  KW, Miller  WL, Maleszewski  JJ, Dispenzieri  A.  Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol  2016;68:1014–1020. PubMed

Gillmore  JD, Damy  T, Fontana  M, Hutchinson  M, Lachmann  HJ, Martinez-Naharro  A, Quarta  CC, Rezk  T, Whelan  CJ, Gonzalez-Lopez  E, Lane  T, Gilbertson  JA, Rowczenio  D, Petrie  A, Hawkins  PN.  A new staging system for cardiac transthyretin amyloidosis. Eur Heart J  2018;39:2799–2806. PubMed

Cheng  RK, Levy  WC, Vasbinder  A, Teruya  S, De Los Santos  J, Leedy  D, Maurer  MS.  Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis. JACC CardioOncol  2020;2:414–424. PubMed PMC

Law  S, Petrie  A, Chacko  L, Cohen  OC, Ravichandran  S, Gilbertson  JA, Rowczenio  D, Wechalekar  A, Martinez-Naharro  A, Lachmann  HJ, Whelan  CJ, Hutt  DF, Hawkins  PN, Fontana  M, Gillmore  JD.  Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Fail  2020;7:3942–3949. PubMed PMC

Maurer  MS, Schwartz  JH, Gundapaneni  B, Elliott  PM, Merlini  G, Waddington-Cruz  M, Kristen  AV, Grogan  M, Witteles  R, Damy  T, Drachman  BM, Shah  SJ, Hanna  M, Judge  DP, Barsdorf  AI, Huber  P, Patterson  TA, Riley  S, Schumacher  J, Stewart  M, Sultan  MB, Rapezzi  C; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med  2018;379:1007–1016. PubMed

Conceição  I, Coelho  T, Rapezzi  C, Parman  Y, Obici  L, Galán  L, Rousseau  A.  Assessment of patients with hereditary transthyretin amyloidosis—understanding the impact of management and disease progression. Amyloid  2019;26:103–111. PubMed

Muchtar  E, Grace  L, Grogan  M.  The challenges in chemotherapy and stem cell transplantation for light-chain amyloidosis. Can J Cardiol  2020;36:384–395. PubMed

Saith  SE, Maurer  MS, Patel  AR.  Systemic amyloidosis due to monoclonal immunoglobulins. Hematol Oncol Clin North Am  2020;34:1055–1068. PubMed

Garcia-Pavia  P, Domínguez  F, Gonzalez-Lopez  E.  Transthyretin amyloid cardiomyopathy. Med Clin (Barc)  2021;156:126–134. PubMed

Palladini  G, Merlini  G.  What is new in diagnosis and management of light chain amyloidosis?  Blood  2016;128:159–168. PubMed

Rapezzi  C, Elliott  P, Damy  T, Nativi-Nicolau  J, Berk  JL, Velazquez  EJ, Boman  K, Gundapaneni  B, Patterson  TA, Schwartz  JH, Sultan  MB, Maurer  MS.  Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT. JACC Heart Fail  2021;9:115–123. PubMed

Adams  D, Gonzalez-Duarte  A, O’Riordan  WD, Yang  C-C, Ueda  M, Kristen  AV, Tournev  I, Schmidt  HH, Coelho  T, Berk  JL, Lin  K-P, Vita  G, Attarian  S, Planté-Bordeneuve  V, Mezei  MM, Campistol  JM, Buades  J, Brannagan  TH, Kim  BJ, Oh  J, Parman  Y, Sekijima  Y, Hawkins  PN, Solomon  SD, Polydefkis  M, Dyck  PJ, Gandhi  PJ, Goyal  S, Chen  J, Strahs  AL, Nochur  SV, Sweetser  MT, Garg  PP, Vaishnaw  AK, Gollob  JA, Suhr  OB.  Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med  2018;379:11–21. PubMed

Benson  MD, Waddington-Cruz  M, Berk  JL, Polydefkis  M, Dyck  PJ, Wang  AK, Planté-Bordeneuve  V, Barroso  FA, Merlini  G, Obici  L, Scheinberg  M, Brannagan  TH  3rd, Litchy  WJ, Whelan  C, Drachman  BM, Adams  D, Heitner  SB, Conceição  I, Schmidt  HH, Vita  G, Campistol  JM, Gamez  J, Gorevic  PD, Gane  E, Shah  AM, Solomon  SD, Monia  BP, Hughes  SG, Kwoh  TJ, McEvoy  BW, Jung  SW, Baker  BF, Ackermann  EJ, Gertz  MA, Coelho  T.  Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med  2018;379:22–31. PubMed